Which of the following statements regarding recommendations for switching therapy in active PsA despite treatment with an OSM is true?
a) Switching to a biologic (TNFi, IL-17i or IL12/23) therapy is preferable to another OSM.
b) Switching to another type of agent is better than adding another OSM to current treatment.
c) Biologic monotherapy is preferable to a combination biologic agent and MTX.
d) b and c only
e). all of the above
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.